SignaCor Therapeutics

SignaCor Therapeutics, based at Queen's University Belfast, is pioneering a novel approach to heart failure treatment. The company focuses on addressing the underlying causes of heart stiffness and enlargement, rather than merely alleviating symptoms. This innovative treatment is administered for just 8 weeks annually, offering a significant reduction in clinic visits and associated healthcare costs. By halting the progression of heart stiffness, SignaCor's solution enhances the quality of life and extends life expectancy for heart failure patients. The business primarily serves the healthcare sector, targeting patients suffering from heart failure. Its business model revolves around the development and potential commercialization of this groundbreaking treatment, which promises to transform patient care by reducing the need for long-term medication. Keywords: heart failure, treatment, heart stiffness, enlargement, quality of life, life expectancy, healthcare, research, Queen's University Belfast, SignaCor Therapeutics.